VDAC2 and bladder transitional cell carcinoma: Importantly, the expression trends of FASN, VDAC2, and RHOT2 in the BLCA and control groups within the TCGA-BLCA and GSE13507 datasets, as well as in clinical samples, were consistent and significant.